Latest news

Hide mandatory notifications of trade

Algeta’s CFO, Øystein Soug, and Ferring‘ s Senior Vice President, Marianne Kock, Nominated to Bionor Pharma`s Board of Directors

Oslo 24.04.2013 - Bionor Pharma (OSE: BIONOR) today announced that Øystein Soug, CFO of the Norwegian listed biotech company Algeta, and Marianne Kock, Vice General Manager of Ferring International Pharma Science Centre (IPC), and Senior Vice President of Regulatory Affairs of Ferring Pharmaceuticals, have been nominated by the Company’s Election Committee to its Board of Directors.

The official election of the Board of Directors will take place at Bionor Pharma’s Annual General Meeting, 15 May.

Øystein Soug joined Algeta in 2008. Since then, Algeta has witnessed extensive growth, with an increase in share price from approx. NOK 8 in Dec. 2008 to around NOK 200 today. Mr. Soug has in this period been responsible for building up the Finance, IR and HR functions of the Company and gained broad experience through two equity fund raisings and one large out-licensing deal to Bayer Pharma AG. Prior to Algeta, he worked six years at the Norwegian industrial group Orkla, lastly as CFO of Orkla’s Russian arm, and previously within Orkla’s Corporate Development division focusing on M&A and strategy. Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development.

Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997. He is a Norwegian citizen and resides in Norway. Marianne Kock joined Ferring Pharmaceuticals A/S in December 2002. She is responsible for Global Regulatory Affairs, Pharmacovigilance, and for the support functions of global archiving & library. She has considerable experience in drug development and contacts with Health Agencies world-wide. She has established a development function in Japan and has also recently set up a development function in China. In addition, she is part of the decision-making group within Ferring Pharmaceuticals.

Ms. Kock is well-educated within science, business and management, and has more than 25 years of experience from a number of high-level positions in the Danish pharmaceutical industry, especially Novo Nordisk A/S. She has vast experience within discovery, development and launch of new pharmaceutical products. Furthermore, she is a member of the Management Board in Ferring Pharmaceuticals A/S, DK and is a Member of the Board of Directors of Ferring Development, US, Izvarino Pharma, Russia and Syntese A/S, DK.  Ms. Kock holds a Master's Degree in Pharmacy and an executive MBA. She is a Danish citizen and resides in Denmark.
Bionor Pharma ASA

Hilde Aalling Syvertsen,
-Director Communications & Corporate Affairs 

Tel +47 23 01 09 60

About Bionor Pharma ASA
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.

Global leader in the development of HIV vaccines
The Company has a leading position in the global research field for therapeutic HIV vaccines, and has two vaccine candidates in the clinical stage of development: Vacc-4x aims to induce long lasting virus control by training immune cells to seek out and kill virus-producing cells, and Vacc-C5 is designed to induce antibodies to HIV that can reduce the harmful hyperactivation of the immune system which can lead to AIDS. The foremost candidate, Vacc-4x, has shown a statistically significant reduction in viral load in a phase II randomized, multinational, double-blind, placebo-controlled study. The Company’s innovative technology platform is also well positioned to develop vaccines for other viral diseases, such as Influenza, HCV (Hepatitis C), HPV (Human papillomavirus) and CMV (Cytomegalovirus).

Four vaccine candidates in development
HIV vaccine, Vacc-4x:
1. Clinical phase II study, combining Vacc-4x with Celgene’s immune modulator Revlimid® (Lenalidomide), to investigate whether Revlimid enhances the effect of Vacc-4x in this placebo-controlled study in HIV patients with an impaired immune system.
2. Clinical phase II study, with Reboost in patients from the previous phase II study, aimed at reducing viral load even further.

HIV vaccine, Vacc-C5: Clinical phase I/II study, to investigate safety and whether the vaccine induces antibodies against HIV in humans.

HIV vaccine, Vacc-HIV (combination of Vacc-4x and Vacc-C5): A preclinical study is in preparation. The rationale behind Vacc-HIV is that this combination should prove more efficacious than each vaccine individually.

Universal influenza vaccine, Vacc-Flu: This vaccine is in the preclinical phase of development. Vacc-Flu is designed to produce long lasting immunity, and to be effective against all seasonal variations of influenza A.

More information about Bionor Pharma is available at

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act).  Vacc-4x, Vacc-C5, Vacc-Flu, Vacc-HCV, Vacc-CMV  and Vacc-HPV are investigational treatments that have not been approved for marketing by any regulatory authority.